Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

40,602 stories, page 407 of 677

Advanced search

🇺🇸Jul 28Researchclinicaltrials.govTier 1 · Trial registry

NCT01109394: Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source

🇺🇸Jul 28Researchclinicaltrials.govTier 1 · Trial registry

NCT00756769: Systemic Lupus Erythematosus in Gullah Health

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source

🇺🇸Jul 28Researchclinicaltrials.govTier 1 · Trial registry

NCT00340405: Development of a Biologic Specimen Bank for the Study of Early Markers of Lung Cancer Among Tin Miners in Yunnan, China

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source

🇺🇸Jul 28Researchclinicaltrials.govTier 1 · Trial registry

NCT00250159: Natural History Study of Patients With Excess Androgen

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source

🇺🇸Jul 28Researchclinicaltrials.govTier 1 · Trial registry

NCT00006150: Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source

🇺🇸Jul 28Researchclinicaltrials.govTier 1 · Trial registry

NCT00001456: Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

FDA Panel Recommends Compounding Unapproved Peptides

조선일보Original source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Aribio Completes Global Phase 3 Trial of AR1001... Topline Results to Be Announced in November

아시아경제Original source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

South Korea joins WHO’s transitional list of top medical device regulators - CHOSUNBIZ

ChosunbizOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Cooley Owes $25.4M Judgment To NJ Biotech Co. Founder

Law360Original source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

These 6 Popular Peptides May Soon Be Easier to Get — Here’s What That Means

Everyday HealthOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

CG Oncology Announces Lancet Oncology Publication of Phase 3 BOND-003 Cohort C Results for Cretostimogene in High-Risk BCG-Unresponsive Bladder Cancer

Quiver QuantitativeOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

About 81% of BOND-003 patients maintained their bladders at 24 months

Stock TitanOriginal source

🌍Jul 28discoverynews.google.comTier 2 · Trade media

Argenx enters biotech buyer class with $2.2B Forte takeout

BioCenturyOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Price to book forward of Lushang Freda Pharmaceutical Co., Ltd. Class A – SSE:600223

TradingViewOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Yale, Biohaven Win $4M In Biotech Trade Secret Trial

Law360Original source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Protecting Biotech Innovation In The Platform Knowledge Era

Law360Original source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Korea’s IMGT launches world-first confirmatory trial for ultrasound drug delivery - CHOSUNBIZ

ChosunbizOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Placebo effect forces Korea biotechs to rethink late-stage trial design - CHOSUNBIZ

ChosunbizOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

These 6 Popular Peptides May Soon Be Easier to Get — Here’s What That Means

YahooOriginal source

🇺🇸Jul 28Researchorbimed.comTier 2 · Direct publisher

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline

OrbiMedOriginal source

🌍Jul 28discoverynews.google.comTier 2 · Trade media

Oak Hill Bio

Fierce BiotechOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Veraxa Biotech (VRXA) moves bispecific ADC VXA-222 program forward

Stock TitanOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

FDA grants orphan drug status to experimental PAH treatment

Pulmonary Hypertension NewsOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

VERAXA Biotech (VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration

NewMediaWireOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Biotech Innovator InstaMed® Pharmaceuticals Appoints Tracy Gibbs, PhD, as Chief Executive Officer Ahead of Worldwide Launch of Non-Injectable Peptide Platform

Yahoo! Finance CanadaOriginal source

🇺🇸Jul 28Researchrarediseases.orgTier 2 · Direct publisher

Laws Shaping Rare Disease Care: TEFRA – Tax Equity and Fiscal Responsibility Act of 1982

NORD Rare DiseasesOriginal source

🌍Jul 28discoverynews.google.comTier 2 · Trade media

RA Capital launches Oak Hill Bio onto the Nasdaq via SPAC

Fierce BiotechOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

FDA Peptide Vote Signals Potential Shift in Compounding and Beauty Regulation

BeautyMatterOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

FDA Approves Simtriyo | PharmExec

Pharmaceutical ExecutiveOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Why is Biohaven Pharmaceutical stock gaining today?

Investing.comOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

First patient enrolled in Phase 3 trial of mocertatug rezetecan for platinum-resistant ovarian cancer

Bioengineer.orgOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

First patient enrolled in GOG-3132/BEHOLD-Ovarian01 phase 3 study evaluating Mocertatug Rezetecan, a novel B7-H4–targeted ADC, in platinum-resistant ovarian cancer

EurekAlert!Original source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Promising biotech stocks with analyst upside targets of up to 242%

Investing.comOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Phase 3 clinical trial enrolls first platinum-resistant ovarian cancer patient

News-MedicalOriginal source

🌍Jul 28Industryeikontx.comTier 1 · Company source

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

Eikon TherapeuticsOriginal source

🇪🇺Jul 28Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Pain relief in palliative care of cancer using home-based neuromodulation and predictive biomarkers

CORDISOriginal source

🇪🇺Jul 28Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: SoluTions foR mItiGatinG climate-induced hEalth tReaths

CORDISOriginal source

🇪🇺Jul 28Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Integrated Services for Infectious Disease Outbreak Research

CORDISOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

FDA Moves to Eliminate Two Food Dye Authorizations

MyChesCoOriginal source

🇪🇺Jul 28Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Co-creation methodology for biotechnology trust-building measures for improved innovation uptake in the bio-based innovation system

CORDISOriginal source

🇪🇺Jul 28Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: PREVENTING AND DELAYING THE DEVELOPMENT OF DIABETES IN AFRICA: A RANDOMISED PLACEBO -CONTROLLED DOUBLE-BLIND PHASE III TRIAL OF METFORMIN IN HIV-INFECTED PERSONS WITH PRE-DIABETES

CORDISOriginal source

🇪🇺Jul 28Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Sustainable eThics Reviews of digital heAlth Technology dEsiGn In sub saharan afriCa

CORDISOriginal source

🇪🇺Jul 28Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer

CORDISOriginal source

🇪🇺Jul 28Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Right-time Adaptive Particle Therapy Of canceR - Personalisation through anatomical plus biological adaptation

CORDISOriginal source

🇪🇺Jul 28Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Oxygen Optimization Therapy through BCPAP for management of childhood pneumonia in general hospitals of LMICs

CORDISOriginal source

🇪🇺Jul 28Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Building a Decolonized Ethics and Governance Framework for Just and Trustworthy AI in Healthcare

CORDISOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

A new ADHD drug just got FDA approval. Here's what makes it different.

KTENOriginal source

🌍Jul 28discoverynews.google.comTier 2 · Trade media

FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’

Fierce PharmaOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Amgen Halts Key Phase 3 Rocatinlimab Study, Resetting Expectations in Dermatology

TipRanksOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Arrowhead completes enrollment in Phase 3 YOSEMITE trial

TipRanksOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Winners And Losers Of Q1: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Branded Pharmaceuticals Stocks

Yahoo! Finance CanadaOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?

Zacks Investment ResearchOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Investors Turn Bullish on This Biotech Stock Heading Into Catalyst

TheStreet ProOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Why the Medicines Hospitals Need Most Are Least Profitable

Pharmaceutical CommerceOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Legend Biotech Shares Fall After CEO Huang Resigns

marketscreener.comOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Branford-based biotech Quantum-Si at risk of Nasdaq delisting, again

Hartford Business JournalOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Taiwan biotech looks outward in next phase of growth

BioWorld NewsOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

AstraZeneca Pressure Puts Krystal Biotech, TG Therapeutics And Gilead Stocks In Focus

simplywall.stOriginal source

🌍Jul 27discoverynews.google.comTier 2 · Trade media

FDA scientists question Capricor data; Legend CEO steps down

BioPharma DiveOriginal source